MedTrace Logo

BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin

NCT02055183 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 162

Last updated 2024-03-15

No results posted yet for this study

Summary

The purpose of the Registry was to evaluate patient safety following Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT®) administration in adult and pediatric patients with a confirmed or suspected exposure to botulinum toxin.

Conditions

  • Botulism

Interventions

DRUG

BAT

Noninterventional, retrospective, observational phase 4 patient Registry

Sponsors & Collaborators

Principal Investigators

  • Jason S Richardson, Ph.D. · Emergent BioSolutions

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-07-31
Completion
2017-07-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02055183 on ClinicalTrials.gov